141 In 2019, the FDA approved solriamfetol (Sunosi) for the treatment of excessive daytime sleepiness in adults with obstructive sleep apnea, which represents an effective option with a more tolerable safety profile
In case of an allergic reaction, please consult a healthcare provider and stop using it immediately
Individuals with compromised gut function, inflammatory conditions, or specific genetic variations affecting peptidase expression may experience even lower effective glutathione uptake from oral capsules
Dopamine is a neurotransmitter associated with pleasure and reward
This excess can harm mitochondria, disrupt axonal transport, and eventually lead to the death of neurons (50)
Neuropsychological effects of occupational exposure to cadmium